The US FDA has accepted Intellia Therapeutics’ application for lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) and ...

Delivering a CRISPR-Cas-derived adenine base editor as a short-lived protein-guide RNA complex enabled efficient PCSK9 ...

Delivering CRISPR-Cas9 as mRNA in lipid nanoparticles preserved the fitness and erythroid potential of edited human ...

A gene-edited pig kidney kept a patient with end-stage kidney disease dialysis-free for 271 days, then failed and was removed without leaving the recipient sensitised against human donors. Eighty-two ...

Precision BioSciences reported progress with its CRISPR-Cas–based ARCUS gene editing therapy PBGENE-DMD, designed to excise dystrophin exons 45–55 and restore near full-length dystrophin expression.

Researchers have used a novel CRISPR-Cas library to identify essential microRNAs in prostate cancer cells, revealing miR-483-3p as a key regulator of cell survival. The study found that disrupting ...

Packing chemical modifications throughout the prime editing guide RNA, rather than only at its ends, raised editing in mouse liver to 67% after a... Delivery: Protein-delivered base editor preserves..

In vivo genome editing is entering an important new phase. Advances in editing technologies, delivery platforms and translational science are bringing the prospect of one-time, directly administered ...

eGenesis announced on Monday that the US FDA has cleared its IND application for EGEN-2784, a multiplex gene-edited pig kidney product, to begin clinical testing in patients with end-stage kidney ...

Using CRISPR-Cas9 screens, researchers in the United States, Belgium and China have identified NR2F2 as a key driver of endocrine resistance in breast cancer. Their findings, published in Science ...

A novel engineered TadA ortholog-derived cytosine base editor (aTdCBE) can overcome existing limitations in motif preferences and adenosine activity seen in current cytosine base editors (CBEs). The ...